ReviewEJNMMI research2023
The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis.
Review in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and Breast MRI for Assessing Tumor Extent and Axillary Metastasis in Breast Cancer: A Histopathology-Referenced Retrospective Study.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Do new guidelines enable a more accurate comparison of [Breast cancer research : BCR · 2026Article
- The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.Nuclear medicine communications · 2026Article
- Comparison between [EJNMMI research · 2026Article
- Diagnostic accuracy of FDG-PET-CT to predict axillary lymph node response after neo-adjuvant chemotherapy in lymph node-positive breast cancer patients.Breast cancer research : BCR · 2026Article
- Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment.Frontiers in oncology · 2026Article
- Per-patient Comparison of [Journal of Cancer · 2026Article
- Prognostic value of molecular and radiologic characteristics on dedicated breast [EJNMMI research · 2025Article
- Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.Clinical and translational science · 2025Article
- A review of the association between baseline [ 18 F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes.Nuclear medicine communications · 2025Review
- Predictive value ofAnnals of nuclear medicine · 2025Article
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Reconstruction of cancer marker analysis with holistic anatomical precision implicates heterogeneity development during breast tumor progression.Discover oncology · 2024Article
- [Insights into imaging · 2024Article
- PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.Journal of clinical medicine · 2024Review
- Evaluation of prognostic risk factors of triple-negative breast cancer withFrontiers in cell and developmental biology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo quantify the relationship between [18F]FDG uptake of the primary tumour measured by PET-imaging with immunohistochemical (IHC) expression of ER, PR, HER2, Ki-67, and clinical subtypes based on these markers in breast cancer patients.
methodsPubMed and Embase were searched for studies that compared SUV
resultsFifty studies were included in the final analysis. SUV
conclusionPrimary tumour SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.